# Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease

> **NCT00471211** · PHASE2 · COMPLETED · sponsor: **Prana Biotechnology Limited** · enrollment: 80 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** PBT2

## Key facts

- **NCT ID:** NCT00471211
- **Lead sponsor:** Prana Biotechnology Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2008-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471211, "Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00471211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*